Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Not yet recruiting × Vulvar Neoplasms × pembrolizumab × Clear all

Phase

Status

Unknown 1 Recruiting 1 Not yet recruiting 1 Completed 1 Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 10 Triple Negative Breast Neoplasms 7 Squamous Cell Carcinoma of Head and Neck 7 Head and Neck Neoplasms 5 Turcot syndrome 3 Prostatic Neoplasms 3 Neoplasm Metastasis 3 Lung Neoplasms 3 Carcinoma, Renal Cell 3 Breast Neoplasms 3 Uterine Cervical Neoplasms 2 Hodgkin Disease 2 Glioblastoma 2 Colorectal Neoplasms 2 Colonic Neoplasms 2 Cholangiocarcinoma 2 Carcinoma, Hepatocellular 2 Biliary Tract Neoplasms 2 Advanced Endometrial Cancer 2 Vulvar Neoplasms 1 To Evaluate the Efficacy of Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Colorectal Carcinoma 1 Thyroid Neoplasms 1 Thoracic Neoplasms 1 Stomach Neoplasms 1 Squamous NSCLC 1 Solid Tumors 1 Respiratory Tract Neoplasms 1 Respiratory Tract Diseases 1 Rare Tumour 1 Primary Glioblastoma 1

Interventions

Indocyanine Green 2 zimberelimab 1 pembrolizumab 1 lenvatinib 1 fludarabine 1 cemiplimab 1 RNA 1 DNA 1 Cyclophosphamide 1 Circulating Tumor DNA 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT07290894 2025-12-18

MITO VULVA-01

National Cancer Institute, Naples

Phase 2 Not yet recruiting

Vulvar Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡